SCHEMBL903340

SCHEMBL903340

OC1COCC(O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20802097 1.00
SCHEMBL18545348 1.00
SCHEMBL9611970 1.00
SCHEMBL22965652 1.00
SCHEMBL38019 0.88
SCHEMBL16134383 0.84 THRB (0.33)
SCHEMBL1079117 0.84 THRB (0.33)
SCHEMBL16134390 0.84 THRB (0.33)
SCHEMBL15579024 0.84 THRB (0.33)
SCHEMBL1079119 0.84 THRB (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114585619-B Alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2024-09-27 CN claimed
EP-4021904-A1 ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES Idorsia Pharmaceuticals Ltd (CH) 2022-07-06 EP claimed
CN-114585619-A alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-06-03 CN claimed
CN-114206893-A (hetero) aryl-methyl-thio-beta-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2022-03-18 CN claimed
EP-2933310-B1 OCTAHYDRO BINAPHTHYL-BASED CHIRAL COMPOUND-CONTAINING LIQUID-CRYSTAL COMPOSITION AND OPTICAL ELEMENT JNC CORP (JP) 2018-06-20 EP claimed
CN-114585619-B Alpha-D-galactopyranoside derivatives 爱杜西亚药品有限公司 2024-09-27 CN disclosed
WO-2024086744-A2 COMPOSITIONS AND USES THEREOF SOLVE THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
WO-2024073610-A2 COMPOSITIONS AND USES THEREOF SOLVE THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
WO-2024005460-A1 COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAME 주식회사 트리오어 2024-01-04 WO disclosed
WO-2023275715-A1 METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS PFIZER INC. (US) 2023-01-05 WO disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-20220193063-A1 METABOLITES OF GLP1R AGONISTS PFIZER INC. (US) 2022-06-23 US disclosed
CN-104854217-B Liquid-crystal composition, mixture, composite, liquid crystal cell and chipal compounds 捷恩智株式会社 2017-06-23 CN disclosed
WO-2017100402-A1 ONE-POT SYNTHESIS OF ANHYDROPENTITOL ESTERS FROM PENTITOLS, CATALYZED BY WATER-TOLERANT LEWIS ACIDS ARCHER DANIELS MIDLAND COMPANY (US) 2017-06-15 WO disclosed
CN-106749233-A One class sulfamide derivative and its application 中山大学 2017-05-31 CN disclosed
US-20160161470-A1 MODULATION OF AXON DEGENERATION GENENTECH, INC. 2016-06-09 US disclosed
US-9101645-B2 Modulation of axon degeneration GENENTECH, INC. (US) 2015-08-11 US disclosed
WO-2015019193-A2 ACYLATED DERIVATIVES OF PHLORIDZIN AND ISOQUERCETRIN AS ANTICANCER THERAPEUTICS AND METHODS OF USE THEREOF DALHOUSIE UNIVERSITY (CA) 2015-02-12 WO disclosed
WO-2012044832-A1 METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS FETZER OLIVER S (US) 2012-04-05 WO disclosed
WO-2011146638-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES CERULEAN PHARMA INC. (US) 2011-11-24 WO disclosed